3Bohrer MP, Baylis C, Robertson CR, et al. Mechanism of the puromycin-induced defects in the transglomerular passage of water and macromolecules. J Clin Invest ,1977, 60:152.
4Ichikawa I, Rennke HG, Hoyer JR, et al. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest, 1983,71:91.
5Bernant DB, Alexander EA, Couser WG,et al. Renal sodium retention during volume expansion in experimental nephrotic syndrome. Kidney Int,1978,14:478.
6Feraille E, Vogt B, Rousselot M, et al. Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest, 1993,91:1295.
7Barlett-Bas C, Khadouri C, Masry S, et al. Enhanced intracellular sodium concentration in kidney cells recruits a latent pool of Na, K-ATPase whose size is modulated by corticosteroids. J Biol Chem , 1990, 265:7 799.
8Yayama K, Konishi K, Ohta A, et al. Elevation of plasma angiotensin in rats with experimentally induced nephrosis. Nephron, 1993,63: 89.
9Wagner J, Gehlen F, Ciechanowicz A, et al. Angiotensin Ⅱ receptor type 1 gene expression in human glomerulonephritis and diabetes mellitus.J Am Soc Nephrol, 1999 , 10:545.
10Parra G, Rodriguez-Iturbe B, Colina-Chourio J, et al. Short term treatment with captopril in hypertension due to chronic glomerulonephritis.Clin Nephrol, 1988 ,29:58.
